Titre :
  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Auteur : Azambuja, Evandro ; Azim, Hatem A ; Holmes, Andrew A.P. ; Holmes, Eileen ; Piccart-Gebhart, Martine ; Di Cosimo, Serena ; Swaby, Ramona R.F. ; Untch, Michael ; Jackisch, Christian ; Lang, Istvan ; Smith, Ian ; Boyle, Frances F. ; Xu, Binghe B. ; Barrios, Carlos ; Perez, Edith A ; Kim, Sung-Bae S.-B. ; Kuemmel, Sherko S. ; Huang, Chiun Sheng C.S. ; Vuylsteke, Peter ; Hsieh, Ruey Kuen R.K. ; Gorbunova, Vera V. ; Eniu, Alexandru A. ; Dreosti, Lydia L. ; Tavartkiladze, Natalia N. ; Gelber, Richard ; Eidtmann, Holger ; Baselga, José
Informations sur la publication : Lancet oncology, 15, 10, (page 1137-1146)
Statut de publication : Publié, 2014
Sujet CREF : Cancérologie
Mots-clés MeSH : Administration, Oral
Adult
Aged
Antibodies, Monoclonal, Humanized -- adverse effects -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
Chemotherapy, Adjuvant
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Infusions, Intravenous
Maximum Tolerated Dose
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness -- pathology
Neoplasm Staging
Quinazolines -- adverse effects -- therapeutic use
Receptor, ErbB-2 -- metabolism
Survival Analysis
Treatment Outcome
Note : SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:1470-2045 
info:doi/10.1016/S1470-2045(14)70320-1
info:pii/S1470204514703201
info:pmid/25130998